PTC Therapeutics, Inc. announced unexpected, yet encouraging results of their product ataluren. The biopharmaceutical company focuses on developing small-molecule drugs that target post-transcriptional control processes to alter protein production. Ataluren is PTC’s investigational new drug designed to restore protein function in cystic fibrosis patients with a nonsense mutation (nmCF)…

Complimentary therapeutic approaches are nothing if not controversial in conventional medicine and mainstream organizations offering information and support for those afflicted with particular diseases. This leaning toward cautious conservatism is commendable, as there is usually plenty of unsubstantiated advice around — often associated with the sale of scientifically unproven…

Vertex Pharmaceuticals, Inc., an international biotech company that has recently been making significant progress in clinical phase research geared towards combating cystic fibrosis, has just announced that they will be presenting during the UBS Global Healthcare Conference. The conference is scheduled to take place at the Sheraton New York Hotel…

San Diego State University postdoctoral researcher Katrine Whiteson, Ph. D. has found that a molecule previously linked to lung injuries in factory workers producing microwave popcorn might also play an important role in microbial lung infections suffered by people with cystic fibrosis (CF). The molecule, known as 2,3-butanedione, which tastes “buttery” and…

The importance of a balanced diet has been highlighted in treatment strategies for several diseases for improving prognoses in patients. The subject of diet and how it affects body composition in patients with cystic fibrosis (CF) is the focus of recent research on how a balanced diet can have…

The Cystic Fibrosis Foundation (CFF) has just given its sought-after Quality Care Award for 2012-2013 to The Cystic Fibrosis Center of Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital. Established back in 2008, the Foundation’s Quality Care Award served to give due recognition to cystic fibrosis (CF) centers that…

Lexington, Massachusetts-based Pulmatrix made an impact at the 2014 Respiratory Drug Delivery Conference being held in Fajardo, Puerto Rico. A poster from the biotechnology company presented data related to PUR0400 (fluoroquinilone Levofloxac), a preclinical drug candidate formulated using Pulmatrix’s proprietary iSPERSE™ dry powder technology. PUR0400 is a drug formulation that…

Since its founding a little over two decades ago, the AbbVie Cystic Fibrosis (CF) Scholarship has been steadfast in its mission to recognize and foster the scholastic capabilities and potential of students afflicted with CF, awarding over $2.4 million worth of scholarships. Now on its 22nd year, the biopharmaceutical-backed…

How today’s healthcare industry approaches cystic fibrosis (CF) has come a long way since the mid-1960s, when individuals diagnosed with CF rarely lived up to the age of 10. Fortunately today, thanks to fervent efforts from all over the globe, those afflicted with this genetic disorder have the chance…

Adding to the excitement of Vertex Pharmaceuticals Inc.‘s new orphan drug status of VX-661 is the announcement of the results of Vertex’s Phase 2 clinical study of…